Medtronic Raises Quarterly Dividend to 72 Cents a Share

Medtronic plc (MDT) increased its quarterly dividend to $0.72 per share from $0.71, extending the healthcare company’s dividend-growth streak to 25 consecutive years, according to locked dividend data for the June 26, 2026, ex-dividend date.

The new payout implies an annual dividend of $2.88 per share. Based on the locked share price of $80.93, the forward annual yield is 3.56%. The increase amounts to 1.41% from the previous quarterly rate.

Medtronic is a major medical-technology company with businesses spanning cardiovascular devices, neuroscience, medical-surgical products and diabetes care. Its scale and breadth make the dividend notable for income-focused investors tracking large healthcare issuers, a sector often valued for recurring demand but still exposed to product cycles, pricing pressure, regulation and procedure volumes. The company’s fiscal reporting describes its portfolio around those core operating groups, with products used across hospitals, clinics and other care settings. SEC filings

The latest increase continues a long dividend record but comes after a relatively modest step-up. Medtronic’s dividend history has included prior annual raises, including an increase reported by The Wall Street Journal for fiscal 2025, underscoring that the company has kept the payout moving higher even as growth rates have been measured. The Wall Street Journal

The locked data also show a dividend safety score of 86 out of 100, equivalent to an A grade, and note that the company previously cut its dividend in 2000. Medtronic’s market capitalization is listed at $103.59 billion, placing it among the larger dividend-paying companies in the healthcare sector.

What It Means for Income Investors

For income investors, the key takeaway is continuity rather than a large reset in income. The quarterly rate moved higher, the annualized payout now stands at $2.88 per share, and the company’s dividend-growth streak reached 25 years. The small percentage increase also signals a cautious pace of payout growth, so investors focused on dividend growth may weigh the durability of the streak against the size of the latest raise and Medtronic’s broader operating performance.